Cargando…

The heart in systemic autoimmune diseases /

This book provides an overview on the current understanding of major complications relating to the heart and autoimmune diseases. It includes the latest information on the new pathogenetic mechanisms involved, along with clinical manifestations of these important comortbidities. Mortality in autoimm...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Atzeni, Fabiola (Editor ), Doria, A. (Andrea) (Editor ), Nurmohamed, Mike (Editor ), Pauletto, Paolo, 1947- (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam, Netherlands : Elsevier, 2017.
Edición:Second edition.
Colección:Handbook of systemic autoimmune diseases ; v. 14.
Temas:
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Front Cover; The Heart in Systemic Autoimmune Diseases; Handbook of Systemic Autoimmune Diseases; Handbook of Systemic Autoimmune Diseases; Copyright; Dedication; Contents; List of Contributors; Preface; 1
  • Cellular Immunity: A Role for Cytokines; 1. INTRODUCTION; 2. AUTOIMMUNITY IN MYOCARDITIS; 3. PATHOGENESIS: THE ROLE OF CELLS AND CYTOKINES; 3.1 Viral Mouse Model; 3.2 Cardiac Myosin Mouse Model; 3.3 Role of Cells; 3.4 Role of Cytokines; 3.5 Summary of Pathogenic Mechanisms; REFERENCES; FURTHER READING; 2
  • Organ-Specific Autoimmunity Involvement in Cardiovascular Disease; 1. INTRODUCTION
  • 2. POST-MYOCARDIAL INFARCTION (DRESSLER) SYNDROME2.1 Anti-Heart Autoantibodies; 3. POST-PERICARDIOTOMY SYNDROME AND IDIOPATHIC RECURRENT ACUTE PERICARDITIS; 3.1 Anti-Heart Autoantibodies; 4. RHEUMATIC CARDITIS; 4.1 Immune Pathogenesis of Rheumatic Carditis; 4.1.1 Antistreptococcus Antibodies; 4.1.2 Anti-heart Autoantibodies; 5. DILATED CARDIOMYOPATHY AND MYOCARDITIS; 5.1 Immune Pathogenesis of Myocarditis and Dilated Cardiomyopathy; 5.2 Anti-Heart Autoantibodies by s-I IFL; 5.3 Anti-Heart Autoantibodies by s-I IFL: Technical Considerations and Proposed Nomenclature
  • 3.6 Other Pathogenetic Mechanisms4. RISK OF DELIVERING A CHILD WITH COMPLETE CHB; 5. CLINICAL MANIFESTATIONS; 5.1 Cardiac Manifestations; 5.2 Non-Cardiac Manifestations; 6. TREATMENT; 6.1 Fluorinated Corticosteroids; 6.2 Other Possible Therapies; 6.3 Postnatal Treatment; 7. OBSTETRIC MANAGEMENT OF PREGNANCIES AT RISK OF DEVELOPING CCHB; 8. PROGNOSIS; 8.1 Infants; 8.2 Maternal; 9. OTHER PREGNANCY OUTCOMES IN WOMEN WITH ANTI-RO/SSA ANTIBODIES; 10. ANTI-RO/SSA NEGATIVE CHB; ACKNOWLEDGMENT; REFERENCES; 4
  • Subclinical Cardiovascular Damage in Systemic Rheumatic Diseases; 1. INTRODUCTION